Nicholas Lydon, Director at Blueprint Medicines Corp (BPMC), sold 50,000 shares at $86.35 ($4.4M) on 2018-02-28, disclosed to the SEC on 2018-03-02.
Open-market sale of $4.4M BPMC by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $86.35 | 4,613 | $398K | 9.1% |
| 2 | $86.35 | 4,613 | $398K | 9.1% |
| 3 | $86.92 | 5,527 | $480K | 10.9% |
| 4 | $86.92 | 5,527 | $480K | 10.9% |
| 5 | $88.20 | 5,264 | $464K | 10.6% |
| 6 | $88.20 | 5,264 |
| $464K |
| 10.6% |
| 7 | $89.03 | 9,596 | $854K | 19.4% |
| 8 | $89.03 | 9,596 | $854K | 19.4% |
| Total | $87.89 avg | 50,000 | $4.4M | 100% |
| Filing → |
| BPMC | SELL | 2020-07-08 | $4.1M | — | Filing → |
| BPMC | SELL | 2020-07-06 | $661K | — | Filing → |
| BPMC | SELL | 2020-06-25 | $32K | — | Filing → |